<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="description" content="drugdevelopR">
<title>Multiarm - Methods for Multi-Arm Programs • drugdevelopR</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.2.2/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.2.2/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Multiarm - Methods for Multi-Arm Programs">
<meta property="og:description" content="drugdevelopR">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.1.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="active nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/Bias_adjustment.html">Methods for Discounting of Phase II Results - Bias Adjustment</a>
    <a class="dropdown-item" href="../articles/Binary_distributed_outcomes.html">Binary Distributed Outcome Variables</a>
    <a class="dropdown-item" href="../articles/Fixed_and_prior_distributions.html">Fixed effects and prior distributions</a>
    <a class="dropdown-item" href="../articles/Interpreting_Output.html">Interpreting the Rest of the Output</a>
    <a class="dropdown-item" href="../articles/More_Parameters.html">More Parameters to Adapt to Specific Settings and Individual Needs</a>
    <a class="dropdown-item" href="../articles/Multiarm_Trials.html">Multiarm - Methods for Multi-Arm Programs</a>
    <a class="dropdown-item" href="../articles/Multiple_Endpoints.html">Multiple_Endpoints</a>
    <a class="dropdown-item" href="../articles/Multitrial.html">Multitrial Programs - Methods for Programs with Several Phase III Trials</a>
    <a class="dropdown-item" href="../articles/Time-to-event_outcomes.html">Time-to-event Outcome Variables</a>
    <a class="dropdown-item" href="../articles/introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul>
<form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off">
</form>

      <ul class="navbar-nav">
<li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>

    
  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Multiarm - Methods for Multi-Arm Programs</h1>
            
      
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/vignettes/Multiarm_Trials.Rmd" class="external-link"><code>vignettes/Multiarm_Trials.Rmd</code></a></small>
      <div class="d-none name"><code>Multiarm_Trials.Rmd</code></div>
    </div>

    
    
<p>Suppose we are planning a drug development program testing the
superiority of an experimental treatment over a control treatment. Our
drug development program consists of an exploratory phase II trial which
is, in case of promising results, followed by a confirmatory phase III
trial.</p>
<p>The drugdevelopR package enables us to optimally plan such programs
using a utility-maximizing approach. To get a brief introduction, we
presented a very basic example on how the package works in <a href="https://sterniii3.github.io/drugdevelopR/articles/introduction-to-drugdevelopR.html">Introduction
to planning phase II and phase III trials with drugdevelopR</a>.
Contrary to the basic setting, when only one phase II and one phase III
trial were conducted, in this scenario we investigate what happens when
multi-arm trials are conducted, i.e. when several different treatments
are ready at the same time, or several doses of the same treatment are
available. The drugdevelopR package enables multi-arm program with two
treatment arms and one control arm, so we can investigate what happens
when two different treatments are ready at the same time or two doses of
the same treatment.</p>
<div class="section level2">
<h2 id="the-example-setting">The example setting<a class="anchor" aria-label="anchor" href="#the-example-setting"></a>
</h2>
<p>Suppose we are developing a new tumor treatment, <em>exper</em>. The
patient variable that we want to investigate is how long the patient
survives without further progression of the tumor (progression free
survival). This is a time to event outcome variable. We want to test two
different doses of of <em>exper</em>, <em>exper1</em> and
<em>exper2</em>. Therefore, we will use the function
<code>optimal_multiarm</code>, which calculates optimal sample sizes and
threshold decisions values for time-to-event outcomes when multi-arm
trials are conducted.</p>
<p>Within our drug development program, we will compare our two
experimental treatments <em>exper1</em> and <em>exper2</em> to the
control treatment <em>contro</em>. The treatment effect measure is given
by <span class="math inline">\(\theta = −\log(HR)\)</span>, which is the
negative logarithm of the hazard ratio <span class="math inline">\(HR\)</span>, which is the ratio of the hazard
rates, for each treatment effect. If we assume that unfavorable events
as tumor progression occur only 75% as often as in the control group for
a specific dose, we have a hazard ratio of 0.75.</p>
</div>
<div class="section level2">
<h2 id="applying-the-package-to-the-example">Applying the package to the example<a class="anchor" aria-label="anchor" href="#applying-the-package-to-the-example"></a>
</h2>
<p>After installing the package according to the <a href="https://sterniii3.github.io/drugdevelopR/#Installation">installation
instructions</a>, we can load it using the following code:</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://github.com/Sterniii3/drugdevelopR" class="external-link">drugdevelopR</a></span><span class="op">)</span></span>
<span><span class="co">#&gt; Loading required package: mvtnorm</span></span>
<span><span class="co">#&gt; Loading required package: doParallel</span></span>
<span><span class="co">#&gt; Loading required package: foreach</span></span>
<span><span class="co">#&gt; Loading required package: iterators</span></span>
<span><span class="co">#&gt; Loading required package: parallel</span></span>
<span><span class="co">#&gt; Loading required package: msm</span></span>
<span><span class="co">#&gt; Loading required package: cubature</span></span></code></pre></div>
<div class="section level3">
<h3 id="defining-all-necessary-parameters">Defining all necessary parameters<a class="anchor" aria-label="anchor" href="#defining-all-necessary-parameters"></a>
</h3>
<p>As, the parameters in the multi-arm setting differ slightly from the
other cases (<a href="https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html">bias
adjustment</a> and <a href="https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html">multitrial</a>),
we will explain them in more detail. Contrary to the basic setting, the
treatment effect are always assumed to be fixed, so the option to use
prior distributions is not available. Nevertheless, some options to
adapt the program to your specific needs are also available in this
setting (see <a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html">More
Paramters</a>), and choosing different treatment effects in phase II and
III are not possible.</p>
<ul>
<li>
<code>hr1</code> is our hazard ratio for the first dose
<em>exper1</em>. As already explained above, we assume that our
experimental treatment <em>exper1</em> leads to unfavorable events
occurring only 75% of times compared to the control treatment
<em>contro</em>. Therefore, we set <code>hr1 = 0.75</code>. Analogously,
<code>hr2</code> is the hazard ratio for our second dose
<em>exper2</em>. For our example, we set <code>hr2 = 0.8</code>.</li>
<li>
<code>ec</code> is the control arm event rate for phase II and III,
how often the unfavorable event occurs in the control group. We assume
that 60% of patients in the group <em>contro</em> have an unfavorable
event, thus, we set <code>ec = 0.6</code>.</li>
<li>
<code>n2min</code> and <code>n2max</code> specify the minimal and
maximal number of participants for the phase II trial. The package will
search for the optimal sample size within this region. For now, we want
the program to search for the optimal sample size in the interval
between 20 and 400 participants. In addition, we will tell the program
to search this region in steps of ten participants at a time by setting
<code>stepn2 = 10</code>.</li>
<li>
<code>hrgomin</code> and <code>hrgomax</code> specify the minimal
and maximal threshold value for the go/no-go decision rule in terms of
the negative logarithm of the hazard ratio. The package will search for
the optimal threshold value within this region. For now, we want the
program to search in the interval between 0.76 and 0.9 while going in
steps of <code>stephrgo = 0.02</code>. Note, that he lower bound of the
decision rule set for represents the smallest size of treatment effect
observed in phase II allowing to go to phase III, so it can be used to
model the minimally clinically relevant effect size. Moreover, note that
the interval specified above corresponds to the set <span class="math inline">\(\{-\log(0.9), ..., -\log(0.76)\}\)</span>.</li>
<li>
<code>c02</code> and <code>c03</code> are fixed costs for phase II
and phase III respectively. We will set the phase II costs to 100 and
the phase III costs to 150 (in <span class="math inline">\(10^5\)</span>$), i.e we have fixed costs of 10 000
000$ in phase II and 15 000 000$ in phase III. Note that the currency of
the input values does not matter, so an input value for <code>c02</code>
of 15 could also be interpreted as fixed costs of 1 500 000€ if
necessary.</li>
<li>
<code>c2</code> and <code>c3</code> are the costs in phase II and
phase III per patient. We will set them to be 0.75 in phase II and 0.1
in phase III. Again, these values are given in <span class="math inline">\(10^5\)</span>$, i.e we have per patient costs of
75 000$ in phase II and 100 000$ in phase III.</li>
<li>
<code>b1</code>, <code>b2</code> and <code>b3</code> are the
expected small, medium and large benefit categories for successfully
launching the treatment on the market for each effect size category in
<span class="math inline">\(10^5\)</span>$. We will define a small
benefit of 1000, a medium benefit of 2000, and a large benefit of 3000.
The effect size categories directly correspond to the treatment effect,
i.e. if the the treatment effect is between 1 and 0.95 (in terms of the
risk ratio) we have a small treatment effect, hence yielding expected
benefits of the drug development program of 100 000 000$.</li>
<li>
<code>alpha</code> is the specified significance level. We will set
<code>alpha = 0.05</code>.</li>
<li>1 - <code>beta</code> type-II error rate for any pair,
i.e. <code>1 - beta</code> is the (any-pair) power for calculation of
the number of events for phase III. We will set <code>beta = 0.1</code>,
meaning that we require a power of 90%.</li>
</ul>
<p>Note, that these parameters may be different to the basic setting,
even if the names are the same. One parameter that is not in the basic
setting is the following parameter:</p>
<ul>
<li>The parameter <code>strategy</code> allows the user to choose
between three strategies. One can select <code>strategy = 1</code> in
which only the best promising candidate of the two doses proceeds to
phase III, <code>strategy = 2</code> in which all promising candidates
proceed to phase III or <code>strategy = 3</code>, in which both
strategies are explored. For our example we want to explore both
settings, so we use <code>strategy = 3</code>.</li>
</ul>
<div class="sourceCode" id="cb2"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">res</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/optimal_multiarm.html">optimal_multiarm</a></span><span class="op">(</span>hr1 <span class="op">=</span> <span class="fl">0.75</span>, hr2 <span class="op">=</span> <span class="fl">0.80</span>, ec <span class="op">=</span> <span class="fl">0.6</span>, <span class="co"># define assumed true HRs and control arm event rate</span></span>
<span>   n2min <span class="op">=</span> <span class="fl">100</span>, n2max <span class="op">=</span> <span class="fl">200</span>, stepn2 <span class="op">=</span> <span class="fl">10</span>,                 <span class="co"># define optimization set for n2</span></span>
<span>   hrgomin <span class="op">=</span> <span class="fl">0.76</span>, hrgomax <span class="op">=</span> <span class="fl">0.9</span>, stephrgo <span class="op">=</span> <span class="fl">0.02</span>,        <span class="co"># define optimization set for HRgo</span></span>
<span>   alpha <span class="op">=</span> <span class="fl">0.05</span>, beta <span class="op">=</span> <span class="fl">0.1</span>,                              <span class="co"># drug development planning parameters</span></span>
<span>   c2 <span class="op">=</span> <span class="fl">0.75</span>, c3 <span class="op">=</span> <span class="fl">1</span>, c02 <span class="op">=</span> <span class="fl">100</span>, c03 <span class="op">=</span> <span class="fl">150</span>,               <span class="co"># define fixed and variable costs for phase II and III</span></span>
<span>   b1 <span class="op">=</span> <span class="fl">1000</span>, b2 <span class="op">=</span> <span class="fl">2000</span>, b3 <span class="op">=</span> <span class="fl">3000</span>,                       <span class="co"># gains for each effect size category</span></span>
<span>   strategy <span class="op">=</span> <span class="fl">3</span>,                                          </span>
<span>   num_cl <span class="op">=</span> <span class="fl">3</span><span class="op">)</span></span></code></pre></div>
</div>
<div class="section level3">
<h3 id="interpreting-the-output">Interpreting the output<a class="anchor" aria-label="anchor" href="#interpreting-the-output"></a>
</h3>
<p>After setting all these input parameters and running the function,
let’s take a look at the output of the program.</p>
<div class="sourceCode" id="cb3"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">res</span></span>
<span><span class="co">#&gt;   Strategy      u HRgo  n2  n3   n  pgo sProg  hr1 hr2  ec   K   N    S  K2  K3</span></span>
<span><span class="co">#&gt; 1        1 261.00 0.84 180 408 588 0.79  0.47 0.75 0.8 0.6 Inf Inf -Inf 235 526</span></span>
<span><span class="co">#&gt; 2        2 246.92 0.80 100 483 583 0.71  0.47 0.75 0.8 0.6 Inf Inf -Inf 175 589</span></span>
<span><span class="co">#&gt;   sProg2 sProg3 steps1 stepm1 stepl1 alpha beta c02 c03   c2 c3   b1   b2   b3</span></span>
<span><span class="co">#&gt; 1   0.47   0.00      1   0.95   0.85  0.05  0.1 100 150 0.75  1 1000 2000 3000</span></span>
<span><span class="co">#&gt; 2   0.21   0.26      1   0.95   0.85  0.05  0.1 100 150 0.75  1 1000 2000 3000</span></span></code></pre></div>
<p>The program returns a data frame, where the output for all
implemented strategies is listed. For strategy 1 (only the best
promising proceeds to phase III) we get:</p>
<ul>
<li>
<code>res$n2</code> is the optimal number of participants for phase
II and <code>res$n3</code> the resulting number of events for phase III.
We see that the optimal scenario requires 180 participants in phase II
and 408 participants in phase III.</li>
<li>
<code>res$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.84 in phase II in order to proceed to phase III.</li>
<li>
<code>res$u</code> is the expected utility of the program for the
optimal sample size and threshold value. In our case it amounts to
261.00, i.e we have an expected utility of 26 100 000$.</li>
</ul>
<p>The results for strategy 2 (all promising proceed to phase III)
are:</p>
<ul>
<li>
<code>res$n2</code> is the optimal number of participants for phase
II and <code>res$n3</code> the resulting number of events for phase III.
We see that the optimal scenario requires 100 participants in phase II
and 483 participants in phase III.</li>
<li>
<code>res$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.80 in phase II in order to proceed to phase III.</li>
<li>
<code>res$u</code> is the expected utility of the program for the
optimal sample size and threshold value. In our case it amounts to
246.92, i.e we have an expected utility of 24 692 000$.</li>
</ul>
<p>We furthermore want to explain the return values <code>sProg</code>,
<code>sProg2</code> and <code>sProg3</code>. Contrary to the basic
setting, <code>sProg2</code> is the probability of a successful program
with only one treatment in phase III and <code>sProg2</code> is the
probability of a successful program with two treatments in phase III.
Hence, for strategy 1 (only the most promising treatment in phase II
proceeds to phase III) <code>sProg = sProg2 = 0.47</code>. With strategy
2 (all promising treatments proceed to phase III), the probability is
the sum of the probability, that both treatments went to phase III
<code>sProg3 = 0.26</code> and the probability that only one treatment
proceeded to phase III <code>sProg2 = 0.21</code>.</p>
</div>
</div>
<div class="section level2">
<h2 id="where-to-go-from-here">Where to go from here<a class="anchor" aria-label="anchor" href="#where-to-go-from-here"></a>
</h2>
<p>In this article we presented an example when multi-arm trials are
conducted. Note, that this example is not restricted to time-to-event
endpoints but can also be applied to binary and normally distributed
endpoints by using the functions <code>optimal_multiarm_binary</code>
and <code>optimal_multiarm_normal</code>. For more information on how to
use the package, see:</p>
<ul>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/introduction-to-drugdevelopR.html"><em>Introduction
to drugdevelopR:</em></a> See how the package works in a basic
example.</li>
<li>
<em>Different outcomes:</em> Apply it to <a href="https://sterniii3.github.io/drugdevelopR/articles/Binary_distributed_outcomes.html">binary
endpoints</a> and <a href="https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html">time-to-event
endpoints</a>.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html"><em>Interpreting
the rest of the output:</em></a> Obtain further details on your drug
development program.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html"><em>Fixed
or prior:</em></a> Model the assumed treatment effect on a prior
distribution.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html"><em>More
parameters:</em></a> Define custom effect size categories. Put
constraints on the optimization by defining maximum costs, the total
expected sample size of the program or the minimum expected probability
of a successful program. Define an expected difference in treatment
effect between phase II and III. Skip phase II.</li>
<li>
<em>Complex drug development programs:</em> Adapt to situations with
<a href="https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html">biased
effect estimators</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html">multiple
phase III trials</a>, or multiple endpoints.</li>
<li>
<em>Parallel computing:</em> Be faster at calculating the optimum by
using parallel computing.</li>
</ul>
</div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p></p>
<p>Developed by Stella Preussler.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p>
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer>
</div>

  

  

  </body>
</html>
